VUMERITY

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, Finland, France, Ireland, Israel, Italy, Lithuania, Poland, Romania, Spain.

Active ingredients

The drug VUMERITY contains one active pharmaceutical ingredient (API):

1	Diroximel fumarate UNII K0N0Z40J3W - DIROXIMEL FUMARATE
	Diroximel fumarate is indicated for the treatment of relapsing forms of multiple sclerosis (MS). The mechanism by which diroximel fumarate exerts therapeutic effects in MS is not fully understood. Diroximel fumarate acts via the major active metabolite, monomethyl fumarate. Preclinical studies indicate that the pharmacodynamic responses of monomethyl fumarate appears to be mediated, at least in part, through activation of the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) transcriptional pathway.
	Read more about Diroximel fumarate

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
VUMERITY Delayed-release capsule	MPI, US: SPL/PLR	FDA, National Drug Code (US)
VUMERITY Gastro-resistant hard capsule	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AX09		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AX Other immunosuppressants
Discover more medicines within L04AX09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1866607, 1866618
ES	Centro de información online de medicamentos de la AEMPS	1211585001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	543763
FR	Base de données publique des médicaments	67170230
IL	מִשְׂרַד הַבְּרִיאוּת	8796
IT	Agenzia del Farmaco	049807011, 049807023
LT	Valstybinė vaistų kontrolės tarnyba	1093690, 1093691
PL	Rejestru Produktów Leczniczych	100462149
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68381001, W68381002
US	FDA, National Drug Code	64406-020